European Journal of Pharmacology 1993: Vol 232 Index

13 Pages·1993·2 MB·English

European Journal of Pharmacology, 232 (1993) 327-329
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999 /93 /$06.00
Author index
Ahrén, B., see Gregersen, S. (232) 35 Coggan, J.S., see Knoper, $.R. (232) 65
Angel, 1., Schoemaker, H., Prouteau, M., Garreau, M. and Langer, Cohen, G., see Evans, J. (232) 241
S.Z Couture, R., see Picard, P. (232) 255
Litoxetine: a selective 5-HT uptake inhibitor with concomitant Currie, PJ. and Wilson, L.M
5-HT, receptor antagonist and antiemetic properties (232) 139 Potentiation of dark onset feeding in obese mice (genotype
Anthony, T.L., see Knoper, $.R. (232) 65 ob /ob) following central injection of norepinephrine and cloni-
Aoyagi, T., see Majima, M. (232) 181 dine (232) 227
Artigas, F., see Bel, N. (232) 326 Czechowska, G., Dziki, M., Pietrasiewicz, T., Kleinrok, Z., Turski,
Aurell, C.-J., see Vilhardt, H. (232) 223 W.A. and Czuczwar, S.J
Competitive antagonists of NMDA receptors, CGP 37849 and
Barnes, P.J., see Kato, M. (232) 7 CGP 39551, enhance the anticonvulsant activity of valproate
Bartfai, T., see Gregersen, S. (232) 35 against electroconvulsions in mice (232) 59
Barth, T., see Vilhardt, H. (232) 223 Czuczwar, S.J., see Czechowska, G. (232) 59
Bassi, L., see Cerri, M.A. (232) 291
Bast, A., see Ter Laak, A.M. (232) 199 Davison, J.S., see Pauletzki, J.G. (232) 263
Bazzoni, G., see Cerri, M.A. (232) 291 De Gaetano, G., see Rotondo, S. (232) 41
Beal, M.F., see Nozaki, K. (232) 295 DeGoede, J., see Berkenbosch, A. (232) 21
Bel, N. and Artigas, F Dejana, E., see Cerri, M.A. (232) 291
Fluvoxamine preferentially increases extracellular 5-hydroxy De Kloet, E.R., see Van Erp, A.M.M. (232) 217
tryptamine in the raphe nuclei: an in vivo microdialysis study Delpon, E., see Pérez-Vizcaino, F. (232) 105
European Journal of Pharmacology, 229 (1992) 101—103 (232) 326 Donné-Op den Kelder, G.M., see Ter Laak, A.M. (232) 199
Beltran-Nufiez, A., see Cerri, M.A. (232) 291 Duarte, J., see Pérez-Vizcaino, F. (232) 105
Bemis, K.G., see Shannon, H.E. (232) 47 Dziki, M., see Czechowska, G. (232) 59
Benthem, L., Scheurink, A.J.W., Van der Leest, J., Leuvenink, H..,
Zijlstra, W.G. and Steffens, A.B Ellinwood, Jr., E.H., see Lee, T.H. (232) 125
Effects of long-term d-fenfluramine treatment on energy Engber, T.M., see Papa, $.M. (232) 247
metabolism in rats (232) 279 Evans, J. and Cohen, G
Berkenbosch, A., Rupreht, J.. DeGoede, J., Olievier, C.N. and Catecholamine uptake inhibitors elevate 6-hydroxydopamine in
Wolsink, J.G brain after administration of 6-hydroxydopa (232) 241
Effects of eseroline on the ventilatory response to CO, (232) 21
Bernasconi, S., see Cerri, M.A. (232) 291 Finklestein, S.P., see Nozaki, K. (232) 295
Bidzseranova, A., Varga, J. and Telegdy, G Fischer, S., Wolf, G., Keilhoff, G. and Hass, P
The effects of brain natriuretic peptide-32 on electroconvulsive Mg’* antagonizes a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
shock-induced amnesia in rats. The role of neurotransmitters pionic acid-induced brain damage and convulsions (232) 121
(232) 305 Franks, R., see Guard, S. (232) 287
Boldry, R.C., see Papa, S.M. (232) 247 Fréhel, D., see Gully, D. (232) 13
Bomzon, A., see Pauletzki, J.G. (232) 263 Furman, B.L. and Sneddon, P
Boucher, S., see Picard, P. (232) 255 Endothelium-dependent vasodilator responses of the isolated
Bouhassira, D., Chitour, D., Villanueva, L. and Le Bars, D mesenteric bed are preserved in long-term streptozotocin diabetic
Morphine and diffuse noxious inhibitory controls in the rat rats (232) 29
effects of lesions of the rostral ventromedial medulla (232) 207
Boye, S.M., see Rompré, P.-P. (232) 299 Garreau, M., see Angel, I. (232) 139
Brown, C.M., see MacKinnon, A.C. (232) 79 Gitter, B.D., see Picard, P. (232) 255
Bymaster, F.P., see Shannon, H.E. (232) 47 Gregersen, S., Lindskog, S., Land, T., Langel, U., Bartfai, T. and
Ahrén, B
Carron, R., see Pérez-Vizcaino, F. (232) 105 Blockade of galanin-induced inhibition of insulin secretion from
Cerletti, C., see Rotondo, S. (232) 41 isolated mouse islets by the non-methionine containing antago
Cerri, M.A., Beltran-Nufiez, A., Bernasconi, S., Dejana, E., Bassi, I nist M35 (232) 35
and Bazzoni, G Grundemar, L., Krstenansky, J.L. and Hakanson, R
Inhibition of cytokine production and endothelial expression of Activation of neuropeptide Y, and neuropeptide Y, receptors by
adhesion antigens by 5'-methylthioadenosine (232) 291 substituted and truncated neuropeptide Y analogs: identification
Chase, T.N., see Papa, $.M. (232) 247 of signal epitopes (232) 271
Chitour, D., see Bouhassira, D. (232) 207 Guard, S., Pain, D., Franks, R. and Watling, KJ
Clapham, J. and Kilpatrick, G.J ['*]JNeurokinin A labels pharmacologically distinct populations
Histamine H, receptor-mediated modulation of water consump of NK. binding sites in hamster and rabbit urinary bladder (232)
tion in the rat (232) 99 287
328
Gully, D., Fréhel, D., Marcy, C., Spinazzé, A., Lespy, L., Neliat, G., McCafferty, D.-M., Kubes, P. and Wallace, J.L.
Maffrand, J.-P. and Le Fur, G. Inhibition of platelet-activating factor-induced leukocyte adhe-
Peripheral biological activity of SR 27897: a new potent non- sion in vivo by a leumedin (232) 169
peptide antagonist of CCK, receptors (232) 13 Meehan, A.G., see Knoper, S.R. (232) 65
Meehan, S.M., see Schechter, M.D. (232) 135
Hakanson, R., see Grundemar, L. (232) 271 Melin, P., see Vilhardt, H. (232) 223
Hass, P., see Fischer, S. (232) 121 Milanés, M.V., see Martinez-Pinero, M.G. (232) 191
Heath, I., see Shannon, H.E. (232) 47 Mitch, C.H., see Shannon, H.E. (232) 47
Holzer, P., see Lippe, I.T. (232) 113 Morikawa, A., see Kato, M. (232) 7
Hoénack, D., see Léscher, W. (232) 147 Mutabagani, K., see Tamura, K. (232) 235
Howbert, J.J., see Picard, P. (232) 255
Neliat, G., see Gully, D. (232) 13
Kato, M., Tokuyama, K., Morikawa, A., Kuroume, T. and Barnes, Nishi, S., see Yamada, S. (232) 1
PJ. Nozaki, K., Finklestein, $.P. and Beal, M.F.
Platelet-activating factor-induced enhancement of superoxide an- Delayed administration of basic fibroblast growth factor protects
ion generation in guinea-pigs (232) 7 against N-methyl-D-aspartate neurotoxicity in neonatal rats (232)
Katori, M., see Majima, M. (232) 181 295
Keilhoff, G., see Fischer, S. (232) 121
Olievier, C.N., see Berkenbosch, A. (232) 21
Kilpatrick, G.J., see Clapham, J. (232) 99
Olverman, H.J., see MacKinnon, A.C. (232) 79
Kleinrok, Z., see Czechowska, G. (232) 59
Knoper, S.R., Meehan, A.G., Purnyn, S., Coggan, J.S., Anthony, T.1
Page, C.P., see Riccio, M.M. (232) 89
and Kreulen, D.L.
Pain, D., see Guard, S. (232) 287
CCK, receptors mediate slow depolarizations in cultured mam-
Papa, S.M., Engber, T.M., Boldry, R.C. and Chase, T.N.
malian sympathetic neurons (232) 65
Opposite effects of NMDA and AMPA receptor blockade on
Kreulen, D.L., see Knoper, S.R. (232) 65
catalepsy induced by dopamine receptor antagonists (232) 247
Krstenansky, J.L., see Grundemar, L. (232) 271
Pauletzki, J.G., Sharkey, K.A., Davison, J.S., Bomzon, A. and Shaf-
Kruk, M.R., see Van Erp, A.M.M. (232) 217
fer, E.A.
Kubes, P., see McCafferty, D.-M. (232) 169
Involvement of L-arginine-nitric oxide pathways in neural relax-
Kuribayashi, Y., see Majima, M. (232) 181
ation of the sphincter of Oddi (232) 263
Kuroume, T., see Kato, M. (232) 7
Pérez-Vizcaino, F., Carrén, R., Delpén, E., Duarte, J. and Tamargo,
Kuttan, S.C. and Sim, M.K.
J
Angiotensin Il-induced tachyphylaxis in aortas of normo- and
Effects of (S)-nafenodone on *Ca** fluxes and contractions in
hypertensive rats: changes in receptor affinity (232) 173
rat isolated vascular smooth muscle (232) 105
Picard, P., Boucher, S., Regoli, D., Gitter, B.D., Howbert, J.J. and
Land, T., see Gregersen, S. (232) 35
Couture, R.
Langel, U., see Gregersen, S. (232) 35
Use of non-peptide tachykinin receptor antagonists to substanti-
Langer, S.Z., see Angel, I. (232) 139
ate the involvement of NK, and NK, receptors in a spinal
Latifpour, J., see Yoshida, M. (232) 159
nociceptive reflex in the rat (232) 255
Le Bars, D., see Bouhassira, D. (232) 207
Pietrasiewicz, T., see Czechowska, G. (232) 59
Lee, T.H., Ellinwood, Jr., E.H. and Zhang, H.
Prouteau, M., see Angel, I. (232) 139
In vitro extracellular recording from nigral dopamine neurons
Purnyn, S., see Knoper, S.R. (232) 65
following continuous d-amphetamine infusion (232) 125
Le Fur, G., see Gully, D. (232) 13 Regoli, D., see Picard, P. (232) 255
Lespy, L., see Gully, D. (232) 13 Riccio, M.M., Manzini, S. and Page, C.P
Leuvenink, H., see Benthem, L. (232) 279 The effect of neonatal capsaicin on the development of bronchial
Lindskog, S., see Gregersen, S. (232) 35 hyperresponsiveness in allergic rabbits (232) 89
Lippe, L.T., Stabentheiner, A. and Holzer, P Rompré, P.-P. and Boye, $.M
Participation of nitric oxide in the mustard oil-induced neuro- Opposite effects of mesencephalic microinjections of cholecys-
genic inflammation of the rat paw skin (232) 113 tokinin octapeptide and neurotensin-(1—13) on brain stimulation
Léscher, W. and Hénack, D reward (232) 299
Profile of ucb LOS9, a novel anticonvulsant drug, in models of Rotondo, S., De Gaetano, G. and Cerletti, C.
partial and generalized epilepsy in mice and rats (232) 147 Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexyla-
mine (IBI P-05006), a thromboxane receptor antagonist (232) 41
MacKinnon, A.C., Stewart, M., Olverman, H.J., Spedding, M. and Rupreht, J., see Berkenbosch, A. (232) 21
Brown, C.M
(*H]p-Aminoclonidine and [*H]idazoxan label different popula- Saito, M., see Majima, M. (232) 181
tions of imidazoline sites on rat kidney (232) 79 Sawyer, B.D., see Shannon, H.E. (232) 47
Maffrand, J.-P., see Gully, D. (232) 13 Schechter, M.D. and Meehan, S.M
Majima, M., Shima, C., Saito, M., Kuribayashi, Y., Katori, M. and Conditioned place preference produced by the psychostimulant
Aoyagi, 1 cathinone (232) 135
Poststatin, a novel inhibitor of bradykinin-degrading enzymes in Scheurink, A.J.W., see Benthem, L. (232) 279
rat urine (232) 181 Schoemaker, H., see Angel, I. (232) 139
Manzini, S., see Riccio, M.M. (232) 89 Shaffer, E.A., see Pauletzki, J.G. (232) 263
Marcy, C., see Gully, D. (232) 13 Shannon, H.E., Sawyer, B.D., Bemis, K.G., Bymaster, F.P., Heath, I.,
Martinez-Pinero, M.G., Vargas, M.L. and Milanés, M.V Mitch, C.H. and Ward, J.S.
L-type Ca** channel ligands modulate morphine effects on the Muscarinic M, receptor agonist actions of muscarinic receptor
hypothalamus-pituitary-adrenocortical axis in rats (232) 191 agonists in rabbit vas deferens (232) 47
Sharkey, K.A., see Pauletzki, J.G. (232) 263 Van Erp, A.M.M., Kruk, M.R. and De Kloet, E.R
Shima, C., see Majima, M. (232) 181 Induction of grooming in resting rats by intracerebroventricular
Shirakawa, O., see Tarazi, F.1. (232) 71 oxytocin but not by adrenocorticotropic hormone-~(1—24) and a-
Sim, M.K., see Kuttan, S.C. (232) 173 melanocyte-stimulating hormone (232) 217
Sneddon, P., see Furman, B.L. (232) 29 Varga, J., see Bidzseranova, A. (232) 305
Spedding, M., see MacKinnon, A.C. (232) 79 Vargas, M.L., see Martinez-Pifero, M.G. (232) 191
Spinazzé, A., see Gully, D. (232) 13 Vijverberg, H.P.M., see Van der Valk, J.B.F. (232) 131
Stabentheiner, A., see Lippe, 1.T. (232) 113 Vilhardt, H., Barth, T., Melin, P. and Aurell, C.-J
Steffens, A.B., see Benthem, L. (232) 279 Antidiuretic activity and release of Factor VIII by vasopressin
Stewart, M., see MacKinnon, A.C. (232) 79 analogues (232) 223
Villanueva, L., see Bouhassira, D. (232) 207
Tamargo, J., see Pérez-Vizcaino, F. (232) 105
Tamminga, C.A., see Tarazi, F.1. (232) 71
Tamura, K., Mutabagani, K. and Wood, J.D Wallace, J.L., see McCafferty, D.-M. (232) 169
Analysis of a nonpeptide antagonist for substance P on myenteric Ward, J.S., see Shannon, H.E. (232) 47
Watling, K.J., see Guard, S. (232) 287
neurons of guinea-pig small intestine (232) 235
Tarazi, F.1., Shirakawa, O. and Tamminga, C.A Weiss, R.M., see Yoshida, M. (232) 159
Low dose raclopride spares the extrapyramidal system in rat Wilson, L.M., see Currie, PJ. (232) 227
brain from metabolic effects (232) 71 Wolf, G., see Fischer, S. (232) 121
Wolsink, J.G., see Berkenbosch, A. (232) 21
Telegdy, G., see Bidzseranova, A. (232) 305
Ter Laak, A.M., Donné-Op den Kelder, G.M., Bast, A. and Tim Wood, J.D., see Tamura, K. (232) 235
merman, H
Is there a difference in the affinity of histamine H, receptor Yamada, S., Yokoo, H. and Nishi, S$
antagonists for CNS and peripheral receptors? An in vitro study Chronic treatment with haloperidol modifies the sensitivity of
(232) 199
autoreceptors that modulate dopamine release in rat striatum
Timmerman, H., see Ter Laak, A.M. (232) 199 (232) 1
Tokuyama, K., see Kato, M. (232) 7 Yokoo, H., see Yamada, S. (232) 1
Turski, W.A., see Czechowska, G. (232) 59 Yoshida, M., Latifpour, J. and Weiss, R.M
Age-related changes in Ca** channel antagonist receptors in
Van der Leest, J., see Benthem, L. (232) 279 rabbit lower urinary tract (232) 159
Van der Valk, J.B.F. and Vijverberg, H.P.M
Chronic sabeluzole treatment of cultured rat cerebellar granule
cells reduces N-methyl-D-aspartate-induced inward current (232) Zhang, H., see Lee, T.H. (232) 125
131 Zijlstra, W.G., see Benthem, L. (232) 279

European Journal of Pharmacology, 232 (1993) 331-338
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999 /93 /$06.00
Key word index
ACTH (adrenocorticotropic hormone) Litoxetine; Emesis; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I.
a-MSH_ (a-melanocyte-stimulating hormone); Behavioural state; (232) 139)
Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp,
A.M.M. (232) 217) 5-HT uptake; Fluvoxamine; Raphe nuclei; Frontal cortex; Microdial-
ysis (in vivo) (Bel, N. (232) 326)
Adenosine analogs
TNF (tumor necrosis factor); Endothelium; Polymorphonuclear Antidiuretic activity
leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291) Factor VIII; Vasopressin analogues; Monkey (Vilhardt, H. (232) 223)
Adherence Anti-inflammatory agents
Inflammation; Microcirculation; Neutrophils; PAF (platelet-activat Adenosine analogs; TNF (tumor necrosis factor); Endothelium; Poly-
ing factor, PAF-acether) (McCafferty, D.-M. (232) 169) morphonuclear leukocytes (Cerri, M.A. (232) 291)
a ,-Adrenoceptors Antiplatelet compound
Feeding; Obese mice; Norepinephrine; Clonidine; Yohimbine (Cur IBI P-05006; Platelets; Thromboxane A, /prostaglandin endoperox-
rie, P.J. (232) 227) ides receptor antagonists (Rotondo, S. (232) 41)
Allergen
Aorta (rat)
Capsaicin; Bronchial hyperresponsiveness; Neonatal treatment (Ric- (S)-Nafenodone; “Ca?* movements; Antidepressants (Pérez-
cio, M.M. (232) 89)
Vizcaino, F. (232) 105)
Alveolar macrophages
Apomorphine
Superoxide anion; PAF (platelet-activating factor, PAF-acether),;
Dopamine release; Striatum; Haloperidol; Sulpiride; (Chronic treat-
Polymorphonuclear leukocytes; Thromboxane A,; (Guinea-pig)
ment) (Yamada, S. (232) 1)
(Kato, M. (232) 7)
[*H]p-Aminoclonidine Autoreceptors
d-Amphetamine; Dopamine; Substantia nigra; Single-unit recording;
{*H]Idazoxan; Imidazoline binding sites; RS-15385-197; Kidney (rat)
(In vitro) (Lee, T.H. (232) 125)
(MacKinnon, A.C. (232) 79)
Amnesia BAY k 8644
pBNP-32 (porcine brain natriuretic peptide-32); Electroconvulsive Ca** channels; Verapamil; Nimodipine; Morphine; Hypothalamus-
shock; (Receptor blockers) (Bidzseranova, A. (232) 305) pituitary-adrenocortical axis; Hypothalamic monoamines; Cortico-
sterone (Martinez-Pifero, M.G. (232) 191)
AMPA (a@-amino-3-hydroxy-5-methy!-4-isoxazolepropionic acid)
Excitotoxicity; Mg?*; Hippocampus; Neurodegeneration; Neuropro Behavioural state
ACTH (adrenocorticotropic hormone); a-MSH (a-melanocyte
tection (Fischer, S. (232) 121)
stimulating hormone); Grooming; Oxytocin; (Intracerebroventricular
d-Amphetamine infusions) (Van Erp, A.M.M. (232) 217)
Dopamine; Substantia nigra; Autoreceptors; Single-unit recording;
(In vitro) (Lee, T.H. (232) 125) Benzamides
Raclopride; Cerebral glucose metabolism (regional); Neuroleptics
Amylase secretion (Tarazi, F.1. (232) 71)
SR 27897; CCK, receptors; Gastric emptying; Gall bladder empty
ing (Gully, D. (232) 13) Bladder
Ontogeny; Ca** channel antagonists; Dihydropyridine; Urethra
Angiotensin Il (Yoshida, M. (232) 159)
Receptor affinity; Smooth muscle (vascular) (Kuttan, $.C. (232) 173)
Bladder (rabbit, hamster)
Anticonvulsant drugs Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Tachykinin
Ucb L059; Seizures; Epilepsy; Piracetam; Valproate (Léscher, W receptor antagonists (Guard, S. (232) 287)
(232) 147)
Blood vessels
Antidepressants Neuropeptide Y; Neuropeptide Y, receptors; Neuropeptide Y, re-
(S)-Nafenodone; Aorta (rat); ““Ca** movements (Pérez-Vizcaino, F ceptors; Vascular neuropeptide Y receptors; Vas deferens
(232) 105) (Grundemar, L. (232) 271)
332
pBNP-32 (porcine brain natriuretic peptide-32) CGP 39551
Electroconvulsive shock; Amnesia; (Receptor blockers) Electroshock (maximal); CGP 37849; Valproate; Seizures
(Bidzseranova, A. (232) 305) (Czechowska, G. (232) 59)
Bradykinin Chemoreflex (central)
Poststatin; Degradation pathway; Urine; Kininase (Majima, M. (232) Breathing; Ventilatory response; CO,; Chemoreflex (peripheral),
181) (Anaesthetized cat) (Berkenbosch, A. (232) 21)
Breathing Chemoreflex (peripheral)
Ventilatory response; CO,; Chemoreflex (central); Chemoreflex (pe- Breathing; Ventilatory response; CO,; Chemoreflex (central);
ripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21) (Anaesthetized cat) (Berkenbosch, A. (232) 21)
Bronchial hyperresponsiveness Cholecystokinin
Capsaicin; Neonatal treatment; Allergen (Riccio, M.M. (232) 89) CCK, receptors; Slow depolarization; Sympathetic neurons (mam-
malian); Electrophysiology; Primary cell culture (Knoper, S.R. (232)
Ca** channel antagonists
65)
Ontogeny; Dihydropyridine; Urethra; Bladder (Yoshida, M. (232)
159)
Nitric oxide (NO); Non-adrenergic, non-cholinergic (NANC) nerves;
Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)
Ca** channels
Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-
Dopamine; Neurotensin; Reward; Ventral tegmental area (Rompré,
pituitary-adrenocortical axis; Hypothalamic monoamines; Cortico-
P.-P. (232) 299)
sterone (Martinez-Pifero, M.G. (232) 191)
Calorimetry (indirect) Clonidine
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Galanin; M35; Islets of Langerhans (isolated); Insulin secretion;
Insulin; Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) Somatostatin (Gregersen, S. (232) 35)
279)
Feeding; Obese mice; Norepinephrine; Yohimbine; a,-Adrenocep-
SCa** movements tors (Currie, P.J. (232) 227)
(S)-Nafenodone; Aorta (rat); Antidepressants (Pérez-Vizcaino, F
(232) 105) co,
Breathing; Ventilatory response; Chemoreflex (central); Chemoreflex
Capsaicin (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)
Bronchial hyperresponsiveness; Neonatal treatment; Allergen (Ric-
cio, M.M. (232) 89) Conditioned place preference
Cathinone; Dopamine; Locomotion; (Rat) (Schechter, M.D. (232)
Carbachol 135)
Muscarinic M, receptors; Muscarinic M, receptor agonists; Vas
deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Corticosterone
McN-A-343 (Shannon, H.E. (232) 47) Ca** channels; Verapamil; Nimodipine; BAY k 8644; Morphine;
Hypothalamus-pituitary-adrenocortical axis; Hypothalamic mono-
Cathinone amines (Martinez-Pinero, M.G. (232) 191)
Conditioned place preference; Dopamine; Locomotion; (Rat)
(Schechter, M.D. (232) 135) Cutaneous vasodilatation
Mustard oil; Neurogenic inflammation; Infrared emission thermogra-
CCK, receptors
phy; Vascular permeability; Nitric oxide (NO); L-NAME (N°-nitro-
SR 27897; Gastric emptying; Gall bladder emptying; Amylase secre-
L-arginine methy! ester) (Lippe, 1.T. (232) 113)
tion (Gully, D. (232) 13)
Degradation pathway
Cholecystokinin; Slow depolarization; Sympathetic neurons (mam-
Poststatin; Bradykinin; Urine; Kininase (Majima, M. (232) 181)
malian); Electrophysiology; Primary cell culture (Knoper, S.R. (232)
65)
Descending inhibitory controls
Cerebellum Pain; Spinal cord; Morphine; Rostral ventromedial medulla (Bouhas-
sira, D. (232) 207)
Sabeluzole; NMDA receptors; Glutamate; Granule cells; Voltage
clamp (Van der Valk, J.B.F. (232) 131)
Desipramine
Histamine H, receptors; Histamine H, receptor antagonists; 6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine), 6-Hydroxydopa-
[*H]Mepyramine; Lung tissue; Selectivity; Sedation (Ter Laak, A.M. mine (6-OHDA); Nomifensine; Neurotoxicity (Evans, J. (232) 241)
(232) 199)
Diabetes
Cerebral glucose metabolism (regional) Streptozotocin; Endothelium; Mesenteric artery; Vasodilatation
Raclopride; Benzamides; Neuroleptics (Tarazi, F.1. (232) 71) (Furman, B.L. (232) 29)
CGP 37849 Dihydropyridine
Electroshock (maximal); CGP 39551; Valproate; Seizures Ontogeny; Ca?* channel antagonists; Urethra; Bladder (Yoshida, M.
(Czechowska, G. (232) 59) (232) 159)
Dopamine Feeding
d-Amphetamine; Substantia nigra; Autoreceptors; Single-unit Obese mice; Norepinephrine; Clonidine; Yohimbine; a ,-Adrenocep-
recording; (In vitro) (Lee, T.H. (232) 125) tors (Currie, PJ. (232) 227
Cathinone; Conditioned place preference; Locomotion; (Rat) bFGF (basic fibroblast growth factor)
(Schechter, M.D. (232) 135) NMDA (N-methyl-D-aspartate), Excitotoxicity (neonate); Neuropro-
tection (Nozaki, K. (232) 295)
Cholecystokinin; Neurotensin; Reward; Ventral tegmental area
(Rompré, P.-P. (232) 299) Fluvoxamine
5-HT uptake; Antidepressants; Raphe nuclei; Frontal cortex; Micro-
Dopamine release dialysis (in vivo) (Bel, N. (232) 326)
Striatum; Haloperidol; Apomorphine; Sulpiride; (Chronic treatment)
(Yamada, S. (232) 1) Free fatty acids
Serotonergic mechanisms (peripheral), Glucose; Insulin; Calorimetry
(indirect), Exercise; (Rat); (Baseline conditions) (Benthem, L. (232)
Electroconvulsive shock
pBNP-32 (porcine brain natriuretic peptide-32); Amnesia; (Receptor 279)
blockers) (Bidzseranova, A. (232) 305)
Frontal cortex
Electrophysiology 5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Micro-
Cholecystokinin; CCK, receptors; Slow depolarization; Sympathetic dialysis (in vivo) (Bel, N. (232) 326)
neurons (mammalian); Primary cell culture (Knoper, S.R. (232) 65)
Galanin
Electroshock (maximal) M35; Islets of Langerhans (isolated); Insulin secretion; Clonidine;
CGP 37849; CGP 39551; Valproate; Seizures (Czechowska, G. (232) Somatostatin (Gregersen, S. (232) 35)
59)
Gall bladder emptying
SR 27897; CCK, receptors; Gastric emptying; Amylase secretion
Emesis
(Gully, D. (232) 13)
Litoxetine; Antidepressants; 5-HT (5-hydroxytryptamine, serotonin)
(Angel, I. (232) 139)
Ganglia
Intestine; Enteric nervous system; Myenteric plexus; Substance P;
Endothelium
Tachykinins (Tamura, K. (232) 235)
Diabetes; Streptozotocin; Mesenteric artery; Vasodilatation (Fur
man, B.L. (232) 29)
Gastric emptying
SR 27897; CCK, receptors; Gall biadder emptying; Amylase secre-
Adenosine analogs; TNF (tumor necrosis factor); Polymorphonuclear
tion (Gully, D. (232) 13)
leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)
Glucose
Enteric nervous system
Serotonergic mechanisms (peripheral); Free fatty acids; Insulin;
Intestine; Ganglia; Myenteric plexus; Substance P; Tachykinins
Calorimetry (indirect); Exercise; (Rat); (Baseline conditions)
(Tamura, K. (232) 235) (Benthem, L. (232) 279)
Epilepsy
Glutamate
Ucb L059; Seizures; Piracetam; Valproate; Anticonvulsant drugs Sabeluzole; NMDA receptors; Cerebellum; Granule cells; Voltage
(Léscher, W. (232) 147) clamp (Van der Valk, J.B.F. (232) 131)
Excitatory amino acids Glutamate receptors
Glutamate receptors; Parkinson’s disease; Neuroleptics (Papa, $.M Excitatory amino acids; Parkinson’s disease; Neuroleptics (Papa,
(232) 247) S.M. (232) 247)
Excitotoxicity Granule cells
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Sabeluzole; NMDA receptors; Glutamate; Cerebellum; Voltage
Mg?*; Hippocampus; Neurodegeneration; Neuroprotection (Fischer, clamp (Van der Valk, J.B.F. (232) 131)
S. (232) 121)
Grooming
Excitotoxicity ( te) ACTH (adrenocorticotropic hormone); a@-MSH (a-melanocyte-
bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspar- stimulating hormone); Behavioural state; Oxytocin; (Intracerebro-
tate); Neuroprotection (Nozaki, K. (232) 295) ventricular infusions) (Van Erp, A.M.M. (232) 217)
Exercise Haloperidol
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Dopamine release; Striatum; Apomorphine; Sulpiride; (Chronic
Insulin; Calorimetry (indirect); (Rat); (Baseline conditions) (Ben- treatment) (Yamada, S. (232) 1)
them, L. (232) 279)
Hippocampus
Factor VIII Excitotoxicity, AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
Antidiuretic activity; Vasopressin analogues; Monkey (Vilhardt, H pionic acid); Mg?*; Neurodegeneration; Neuroprotection (Fischer,
(232) 223) S. (232) 121)
334
Hippocampus (rat) Insulin
Muscarinic M, receptors; Muscarinic M, receptor agonists; Vas Serotonergic mechanisms (peripheral); Glucose; Free fatty acids;
deferens (rabbit); Pirenzepine; Oxotremorine-M; Carbachol; McN Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Ben
A-343 (Shannon, H.E. (232) 47) them, L. (232) 279)
Histamine Insulin secretion
Nitric oxide (NO); Cholecystokinin; Non-adrenergic, non-cholinergic Galanin; M35; Islets of Langerhans (isolated); Clonidine; Somato-
(NANC) nerves; Sphincter of Oddi (Pauletzki, J.G. (232) 263) statin (Gregersen, S. (232) 35)
Histamine H, receptor antagonists Intestine
Histamine H, receptors; [°H]Mepyramine; Lung tissue; Cerebellum; Ganglia; Enteric nervous system; Myenteric plexus; Substance P;
Selectivity; Sedation (Ter Laak, A.M. (232) 199) Tachykinins (Tamura, K. (232) 235)
Histamine H, receptors Islets of Langerhans (isolated)
Histamine H, receptor antagonists; [“~H)]Mepyramine; Lung tissue; Galanin; M35; Insulin secretion; Clonidine; Somatostatin (Greger-
Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199) sen, S. (232) 35)
Histamine H, receptors Kidney (rat)
(R)-a-Methylhistamine; Thioperamide; Water consumption; (Rat) [*H]p-Aminoclonidine; [*H]Idazoxan; Imidazoline binding sites; RS
(Clapham, J. (232) 99) 15385-197 (MacKinnon, A.C. (232) 79)
5-HT (5-hydroxytryptamine, serotonin) Kininase
Litoxetine; Antidepressants; Emesis (Angel, I. (232) 139) Poststatin; Bradykinin; Degradation pathway; Urine (Majima, M
(232) 181)
5-HT uptake
Litoxetine
Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex; Micro-
dialysis (in vivo) (Bel, N. (232) 326) Antidepressants; Emesis; 5-HT (5-hydroxytryptamine, serotonin)
(Angel, I. (232) 139)
6-Hydroxydopamine (6-OHDA)
Locomotion
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); Nomifensine; De
Cathinone; Conditioned place preference Dopamine; (Rat)
sipramine; Neurotoxicity (Evans, J. (232) 241)
(Schechter, M.D. (232) 135)
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine )
Lung tissue
6-Hydroxydopamine (6-OHDA); Nomifensine; Desipramine; Neuro-
Histamine H, receptors; Histamine H, receptor antagonists;
toxicity (Evans, J. (232) 241)
[*H]Mepyramine; Cerebellum; Selectivity; Sedation (Ter Laak, A.M
(232) 199)
Hypothalamic monoamines
Ca** channels; Verapamil; Nimodipine; BAY k 8644; Morphine;
M35
Hypothalamus-pituitary-adrenocortical axis; Corticosterone (Marti
Galanin; Islets of Langerhans (isolated); Insulin secretion; Clonidine;
nez-Pinero, M.G. (232) 191)
Somatostatin (Gregersen, S. (232) 35)
Hypothalamus-pituitary-adrenocortical axis
McN-A-343
Ca?* channels; Verapamil; Nimodipine; BAY k 8644; Morphine;
Muscarinic M, receptors; Muscarinic M, receptor agonists; Vas
Hypothalamic monoamines; Corticosterone (Martinez-Pifero, M.G
deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M;
(232) 191) Carbachol (Shannon, H.E. (232) 47)
IBI P-05006
{°H]Mepyramine
Antiplatelet compound; Platelets; Thromboxane A, /prostaglandin
Histamine H, receptors; Histamine H, receptor antagonists; Lung
endoperoxides receptor antagonists (Rotondo, S. (232) 41)
tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)
[> H)Idazoxan
Mesenteric artery
[°H]p-Aminoclonidine; Imidazoline binding sites; RS-15385-197; Diabetes; Streptozotocin; Endothelium; Vasodilatation (Furman,
Kidney (rat) (MacKinnon, A.C. (232) 79) B.L. (232) 29)
Imidazoline binding sites (R)-a@-Methylhistamine
[°H]p-Aminoclonidine; [*H]Idazoxan; RS-15385-197; Kidney (rat) Histamine H, receptors; Thioperamide; Water consumption; (Rat)
(MacKinnon, A.C. (232) 79) (Clapham, J. (232) 99)
Inflammation Mg?*
Adherence; Microcirculation; Neutrophils; PAF (platelet-activating Excitotoxicity,; AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
factor, PAF-acether) (McCafferty, D.-M. (232) 169) pionic acid); Hippocampus; Neurodegeneration; Neuroprotection
(Fischer, S. (232) 121)
Infrared emission thermography
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Microcirculation
Vascular permeability; Nitric oxide (NO); L-NAME (N°-nitro-L- Inflammation; Adherence; Neutrophils; PAF (platelet-activating fac-
arginine methyl ester) (Lippe, I.T. (232) 113) tor, PAF-acether) (McCafferty, D.-M. (232) 169)
Microdialysis (in vivo) Neurokinin receptor antagonists
5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Frontal NK, receptors; NK, receptors; Spinal cord; Nociception (Picard, P
cortex (Bel, N. (232) 326) (232) 255)
Monkey Neurokinin receptor subtypes
Factor VIII; Antidiuretic activity; Vasopressin analogues (Vilhardt, Tachykinin; Neurokinin A; Tachykinin receptor antagonists; Bladder
H. (232) 223) (rabbit, hamster) (Guard, S. (232) 287)
Morphine Neuroleptics
Ca** channels; Verapamil; Nimodipine; BAY k 8644; Hypothala Raclopride; Cerebral glucose metabolism (regional); Benzamides
mus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corti (Tarazi, F.1. (232) 71)
costerone (Martinez-Pinero, M.G. (232) 191)
Excitatory amino acids; Glutamate receptors; Parkinson’s disease
(Papa, S.M. (232) 247)
Pain; Spinal cord; Descending inhibitory controls; Rostral ventrome
dial medulla (Bouhassira, D. (232) 207)
Neuropeptide Y
Neuropeptide Y, receptors; Neuropeptide Y, receptors; Vascular
a-MSH (a-melanocyte-stimulating hormone)
neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar,
ACTH (adrenocorticotropic hormone); Behavioural state; Grooming;
L. (232) 271)
Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232)
217)
Neuropeptide Y, receptors
Neuropeptide Y; Neuropeptide Y, receptors; Vascular neuropeptide
Muscarinic M, receptor agonists
Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)
Muscarinic M, receptors; Vas deferens (rabbit); Hippocampus (rat);
Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon Neuropeptide Y, receptors
H.E. (232) 47)
Neuropeptide Y; Neuropeptide Y, receptors; Vascular neuropeptide
Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)
Muscarinic M, receptors
Muscarinic M, receptor agonists; Vas deferens (rabbit); Hippocam Neuroprotection
pus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 Excitotoxicity, AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
(Shannon, H.E. (232) 47) pionic acid); Mg~*; Hippocampus; Neurodegeneration (Fischer, S
(232) 121)
Mustard oil
Neurogenic inflammation; Cutaneous vasodilatation; Infrared emis bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspar
sion thermography; Vascular permeability; Nitric oxide (NO), I tate); Excitotoxicity (neonate) (Nozaki, K. (232) 295)
NAME (N“-nitro-L-arginine methyl ester) (Lippe, 1.T. (232) 113)
Neurotensin
Myenteric plexus Cholecystokinin; Dopamine; Reward; Ventral tegmental area
Intestine; Ganglia; Enteric nervous system; Substance P; Tachykinins (Rompré, P.-P. (232) 299)
(Tamura, K. (232) 235)
Neurotoxicity
(S)-Nafenodone 6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopa-
Aorta (rat); ““Ca** movements; Antidepressants (Pérez-Vizcaino, I mine (6-OHDA); Nomifensine; Desipramine (Evans, J. (232) 241)
(232) 105)
Neutrophils
Inflammation; Adherence; Microcirculation; PAF (platelet-activating
L-NAME (N® -nitro-L-arginine methyl ester)
factor, PAF-acether) (McCafferty, D.-M. (232) 169)
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation;
Infrared emission thermography; Vascular permeability; Nitric oxide
Nimodipine
(NO) (Lippe, LT. (232) 113)
Ca** channels; Verapamil; BAY k 8644; Morphine; Hypothalamus-
pituitary-adrenocortical axis; Hypothalamic monoamines; Cortico-
Neonatal treatment
sterone (Martinez-Pinero, M.G. (232) 191)
Capsaicin; Bronchial hyperresponsiveness; Allergen (Riccio, M.M
(232) 89)
Nitric oxide (NO)
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation;
Neurodegeneration Infrared emission thermography; Vascular permeability, L-NAME
Excitotoxicity, AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepro (N“-nitro-L-arginine methyl ester) (Lippe, 1.T. (232) 113)
pionic acid); Mg’ *; Hippocampus; Neuroprotection (Fischer, S. (232)
121) Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves
Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)
Neurogenic inflammation
Mustard oil; Cutaneous vasodilatation; Infrared emission thermogra- NK, receptors
phy; Vascular permeability; Nitric oxide (NO); L-NAME (N°-nitro Neurokinin receptor antagonists; NK, receptors; Spinal cord; Noci-
L-arginine methyl ester) (Lippe, LT. (232) 113) ception (Picard, P. (232) 255)
Neurokinin A NK, receptors
Tachykinin; Neurokinin receptor subtypes; Tachykinin receptor an Neurokinin receptor antagonists; NK, receptors; Spinal cord; Noci-
tagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287) ception (Picard, P. (232) 255)
336
NMDA (N-methy!-D-aspartate) Platelets
bFGF (basic fibroblast growth factor); Excitotoxicity (neonate); Neu- Antiplatelet compound; IBI P-05006; Thromboxane A, /pros-
roprotection (Nozaki, K. (232) 295) taglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)
NMDA receptors Polymorphonuclear leukocytes
Sabeluzole; Glutamate; Cerebellum; Granule cells; Voltage clamp Superoxide anion; PAF (platelet-activating factor, PAF-acether);
(Van der Valk, J.B.F. (232) 131) Alveolar macrophages; Thromboxane A,; (Guinea-pig) (Kato, M.
(232) 7)
Nociception
Neurokinin receptor antagonists; NK, receptors; NK, receptors; Adenosine analogs; TNF (tumor necrosis factor); Endothelium;
Spinal cord (Picard, P. (232) 255) Anti-inflammatory agents (Cerri, M.A. (232) 291)
Poststatin
Nomifensine
Bradykinin; Degradation pathway; Urine; Kininase (Majima, M. (232)
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopa-
181)
mine (6-OHDA); Desipramine; Neurotoxicity (Evans, J. (232) 241)
Primary cell culture
Non-adrenergic, non-cholinergic (NANC) nerves
Cholecystokinin; CCK, receptors; Slow depolarization; Sympathetic
Nitric oxide (NO); Cholecystokinin; Sphincter of Oddi; Histamine
neurons (mammalian); Electrophysiology (Knoper, S.R. (232) 65)
(Pauletzki, J.G. (232) 263)
Raclopride
Norepinephrine Cerebral glucose metabolism (regional); Benzamides; Neuroleptics
Feeding; Obese mice; Clonidine; Yohimbine; a,-Adrenoceptors
(Tarazi, F.1. (232) 71)
(Currie, P.J. (232) 227)
Raphe nuclei
Obese mice 5-HT uptake; Fluvoxamine; Antidepressants; Frontal cortex; Micro-
Feeding; Norepinephrine; Clonidine; Yohimbine; a,-Adrenoceptors dialysis (in vivo) (Bel, N. (232) 326)
(Currie, P.J. (232) 227)
Receptor affinity
Ontogeny Angiotensin II; Smooth muscle (vascular) (Kuttan, $.C. (232) 173)
Ca** channel antagonists; Dihydropyridine; Urethra; Bladder
(Yoshida, M. (232) 159) Reward
Cholecystokinin; Dopamine; Neurotensin; Ventral tegmental area
Oxotremorine-M (Rompré, P.-P. (232) 299)
Muscarinic M, receptors; Muscarinic M, receptor agonists; Vas
deferens (rabbit); Hippocampus (rat); Pirenzepine; Carbachol; McN- Rostral ventromedial medulla
A-343 (Shannon, H.E. (232) 47) Pain; Spinal cord; Morphine; Descending inhibitory controls
(Bouhassira, D. (232) 207)
Oxytocin
ACTH (adrenocorticotropic hormone); a-MSH (a-melanocyte- RS-15385-197
stimulating hormone); Behavioural state; Grooming; (Intracerebro- [*H]p-Aminoclonidine; [*H]Idazoxan; Imidazoline binding sites; Kid-
ventricular infusions) (Van Erp, A.M.M. (232) 217) ney (rat) (MacKinnon, A.C. (232) 79)
PAF (platelet-activating factor, PAF-acether) Sabeluzole
Superoxide anion; Alveolar macrophages; Polymorphonuclear leuko- NMDA receptors; Glutamate; Cerebellum; Granule cells; Voltage
cytes; Thromboxane A; (Guinea-pig) (Kato, M. (232) 7) clamp (Van der Valk, J.B.F. (232) 131)
Sedation
Inflammation; Adherence; Microcirculation; Neutrophils (Mc-
Histamine H, receptors; Histamine H, receptor antagonists;
Cafferty, D.-M. (232) 169)
[*H]Mepyramine; Lung tissue; Cerebellum; Selectivity (Ter Laak,
A.M. (232) 199)
Pain
Spinal cord; Morphine; Descending inhibitory controls; Rostral ven-
Seizures
tromedial medulla (Bouhassira, D. (232) 207)
Electroshock (maximal); CGP 37849; CGP 39551; Valproate
(Czechowska, G. (232) 59)
Parkinson’s disease
Excitatory amino acids; Glutamate receptors; Neuroleptics (Papa, Ucb L059; Epilepsy; Piracetam; Valproate; Anticonvulsant drugs
S.M. (232) 247) (Léscher, W. (232) 147)
Piracetam Selectivity
Ucb L059; Seizures; Epilepsy; Valproate; Anticonvulsant drugs Histamine H, receptors; Histamine H, receptor antagonists;
(Léscher, W. (232) 147) [°H]Mepyramine; Lung tissue; Cerebellum; Sedation (Ter Laak, A.M.
(232) 199)
Pirenzepine
Muscarinic M, receptors; Muscarinic M, receptor agonists; Vas Serotonergic mechanisms (peripheral)
deferens (rabbit); Hippocampus (rat); Oxotremorine-M; Carbachol; Glucose; Free fatty acids; Insulin; Calorimetry (indirect); Exercise;
McN-A-343 (Shannon, H.E. (232) 47) (Rat); (Baseline conditions) (Benthem, L. (232) 279)